Morgan Stanley Upgrades Novartis to Overweight, Sees Favorable Valuation Amid Rhapsodo Launch

miércoles, 3 de diciembre de 2025, 12:11 pm ET1 min de lectura
MS--
NVS--

Morgan Stanley has upgraded Novartis to overweight from equal-weight due to a valuation pullback after the company missed on the bottom line in Q3 results and optimism over the upcoming launch of Rhapsodo.

Morgan Stanley Upgrades Novartis to Overweight, Sees Favorable Valuation Amid Rhapsodo Launch

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios